Zymeworks BC Inc (NASDAQ: ZYME) has seen a decline in its stock price by -5.98 in relation to its previous close of 14.55. However, the company has experienced a -15.87% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-21 that VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
Is It Worth Investing in Zymeworks BC Inc (NASDAQ: ZYME) Right Now?
Moreover, the 36-month beta value for ZYME is 1.13. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZYME is 67.09M and currently, short sellers hold a 7.01% of that float. On November 22, 2024, ZYME’s average trading volume was 615.77K shares.
ZYME’s Market Performance
ZYME stock saw an increase of -15.87% in the past week, with a monthly gain of 4.35% and a quarterly increase of 20.11%. The volatility ratio for the week is 6.02%, and the volatility levels for the last 30 days are 5.21% for Zymeworks BC Inc (ZYME). The simple moving average for the last 20 days is -9.00% for ZYME stock, with a simple moving average of 24.90% for the last 200 days.
Analysts’ Opinion of ZYME
Many brokerage firms have already submitted their reports for ZYME stocks, with Leerink Partners repeating the rating for ZYME by listing it as a “Outperform.” The predicted price for ZYME in the upcoming period, according to Leerink Partners is $25 based on the research report published on November 07, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see ZYME reach a price target of $12. The rating they have provided for ZYME stocks is “Equal Weight” according to the report published on November 01st, 2024.
Wells Fargo gave a rating of “Overweight” to ZYME, setting the target price at $12 in the report published on March 21st of the previous year.
ZYME Trading at -0.17% from the 50-Day Moving Average
After a stumble in the market that brought ZYME to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.71% of loss for the given period.
Volatility was left at 5.21%, however, over the last 30 days, the volatility rate increased by 6.02%, as shares surge +5.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.32% upper at present.
During the last 5 trading sessions, ZYME fell by -15.87%, which changed the moving average for the period of 200-days by +20.74% in comparison to the 20-day moving average, which settled at $15.03. In addition, Zymeworks BC Inc saw 31.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZYME starting from Galbraith Kenneth, who sale 18,198 shares at the price of $10.65 back on Jan 05 ’24. After this action, Galbraith Kenneth now owns 29,468 shares of Zymeworks BC Inc, valued at $193,849 using the latest closing price.
Galbraith Kenneth, the Chair & CEO of Zymeworks BC Inc, sale 5,706 shares at $11.22 during a trade that took place back on Jan 08 ’24, which means that Galbraith Kenneth is holding 23,762 shares at $63,996 based on the most recent closing price.
Stock Fundamentals for ZYME
Current profitability levels for the company are sitting at:
- -1.95 for the present operating margin
- -0.02 for the gross margin
The net margin for Zymeworks BC Inc stands at -481.26. The total capital return value is set at -0.0. Equity return is now at value -28.73, with -21.79 for asset returns.
Based on Zymeworks BC Inc (ZYME), the company’s capital structure generated 0.99 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 89.32. The interest coverage ratio of the stock is -16.77.
Currently, EBITDA for the company is -129.96 million with net debt to EBITDA at 0.94. When we switch over and look at the enterprise to sales, we see a ratio of 13.51. The receivables turnover for the company is 0.0for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.10.
Conclusion
To wrap up, the performance of Zymeworks BC Inc (ZYME) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
